Martin Smit, co-director of BiomarkerBay, has answered three questions about the role of BiomarkerBay in the field of biomarker research.
My name is Martin Smit and I am one of the founders and now co-director of BiomarkerBay. I am a professional with long-standing experience in pharmaceutical industry, specifically R&D. I am also director of the Graduate School of Medical Sciences at the University Medical Center Groningen and Program Manager Life Sciences of the Healthy Ageing Network Northern Netherlands.
BiomarkerBay makes available to customers complex assets, both know-how and material, such as biomarker assays, samples from many different patient cohorts, and bioanalytical capabilities. This region of the Netherlands is specifically of interest because of the large density of know-how in the area of biomarkers both from academic institutes and internationally recognized contract research organisations.
BiomarkerBay provides in fact a single-point of contact for customers who have complex questions. I really like to be able to deliver on these usually clinically relevant questions. For the University Medical Center it makes it possible to create synergy between its know-how and capabilities and the research questions from industry. We need the latter to translate the science into valuable products in evidence based medicine.
